STOCKS NEWS EUROPE-Getinge falls on U.S. regulatory worries

(Adds dropped word 'falls' to headline)

Shares in Getinge (Other OTC: GNGBF - news) fall 7.5 percent after the Swedish medical technology firm postpones its capital markets' day as a result of discussions with the U.S. Food & Drug Administration (FDA) related to quality issues at its Medical Systems unit.

"The market is likely to speculate that dialogue is progressing worse than expected and associated costs are potentially higher than expected. New financial targets at the CMD were central to our positive stance," Danske Banke says in a note, downgrading its recommendation on the share to hold from buy.

Handelsbanken Capital markets says in a note the FDA could decide to fine the company or take other actions.

"If the FDA decides to curtail products shipped or orders a shutdown of a production plant (Wayne or Hudson plants at risk), this should have significant negative impact on the group's financial performance," the bank says, adding 30 percent of group sales were in the United States last year.

"Getinge Group will hold its capital markets' day when it has more to report about these discussions, their potential financial impact on the company and the latest progress being made in strengthening Medical Systems' quality management systems," the company said in a statement late on Sunday.

Getinge issued its third profit warning in just over a year in March as it said it faced more than a year of heavy spending to improve controls following inspections by the U.S. FDA.

Reuters messaging rm://sven.nordenstam.reuters.com@reuters.net